Treating Penile Cancer in the Immunotherapy and TargetedTherapy Era

While localized penile cancers are typically treated surgically and metastatic penile cancers benefit from standard chemotherapy,there have been studies on the horizon demonstrating immunotherapy as a novel approach to metastatic penile cancers thathave failed standard chemotherapy. We report a case series of two patients who improved on immunotherapy after progressingwith standard chemotherapy regimens. Thefirst case describes a 64-year-old male with a penile mass and significantlymphadenopathy who had surgical resection and adjuvant chemotherapy prior to continued disease progression. He wasstarted on anti-EGFR treatment and improved initially, but he eventually had progression of disease. The second case describesa 79-year-old male with a penile mass who was treated with surgical resection and started on adjuvant chemoradiation, but hedeveloped recurrence and nodal involvement. Therefore, second-line therapy of the PD-L1 inhibitor was started in this patient.There were no available clinical trials for penile cancer patients who progressed beyond the standard surgical therapy andchemotherapy